Auxesis Pharma is the first company globally to successfully stabilize acetylsalicylic acid (ASA) in liquid form. This breakthrough enables a new category of topical pharmaceutical products for localized pain and skin irritation, with the potential to transform treatment approaches in both human and veterinary medicine.
Through a major scientific breakthrough, Auxesis Pharma has resolved a chemical challenge long considered impossible. The formulation meets established stability requirements, and the company is now advancing toward production scale-up, regulatory processes and commercial launch.
Background
Acetylsalicylic acid is one of the world’s most widely used pharmaceutical substances. Historically, it has only been available in tablet form due to instability in liquid formulations. A stable liquid ASA preparation has long been sought but had not previously been successfully developed.
Next Steps
The company is currently finalizing manufacturing preparations, progressing regulatory activities and planning market introduction, initially in the Nordic region followed by international expansion.
Contact
Auxesis Pharma Holding AB (publ)